Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Similar articles for PubMed (Select 23708872)

1.

177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.

Jiang L, Miao Z, Liu H, Ren G, Bao A, Cutler CS, Shi H, Cheng Z.

Nucl Med Commun. 2013 Sep;34(9):909-14. doi: 10.1097/MNM.0b013e328362d2b6.

PMID:
23708872
2.

64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.

Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ.

Nucl Med Biol. 2012 Apr;39(3):377-87. doi: 10.1016/j.nucmedbio.2011.10.004. Epub 2012 Jan 5.

3.

Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy.

Cui L, Liu Z, Jin X, Jia B, Li F, Wang F.

Nucl Med Biol. 2013 Feb;40(2):182-9. doi: 10.1016/j.nucmedbio.2012.11.002. Epub 2012 Nov 28.

PMID:
23199569
4.

(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging.

Liu Z, Niu G, Wang F, Chen X.

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1483-94. doi: 10.1007/s00259-009-1123-z. Epub 2009 Apr 10.

PMID:
19360404
5.

A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu L, Miao Y, Reynolds TS, Smith CJ.

Nucl Med Biol. 2014 Feb;41(2):133-9. doi: 10.1016/j.nucmedbio.2013.11.006. Epub 2013 Nov 28.

6.

(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.

Liu Z, Yan Y, Liu S, Wang F, Chen X.

Bioconjug Chem. 2009 May 20;20(5):1016-25. doi: 10.1021/bc9000245.

7.

Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.

Chakraborty S, Sarma HD, Vimalnath KV, Pillai MR.

Nucl Med Biol. 2013 Oct;40(7):946-54. doi: 10.1016/j.nucmedbio.2013.05.011. Epub 2013 Jul 11.

PMID:
23850487
8.

Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.

Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.

Nucl Med Biol. 2013 Nov;40(8):1025-34. doi: 10.1016/j.nucmedbio.2013.07.005. Epub 2013 Aug 19.

PMID:
23969085
9.

18F-labeled BBN-RGD heterodimer for prostate cancer imaging.

Li ZB, Wu Z, Chen K, Ryu EK, Chen X.

J Nucl Med. 2008 Mar;49(3):453-61. doi: 10.2967/jnumed.107.048009. Epub 2008 Feb 20.

10.

99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma.

Liu Z, Huang J, Dong C, Cui L, Jin X, Jia B, Zhu Z, Li F, Wang F.

Mol Pharm. 2012 May 7;9(5):1409-17. doi: 10.1021/mp200661t. Epub 2012 Apr 11.

PMID:
22452411
11.

Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ.

Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001. Epub 2014 Jan 10.

12.

177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.

Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD.

J Nucl Med. 2006 Jul;47(7):1144-52.

13.

Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN.

Liu Z, Yan Y, Chin FT, Wang F, Chen X.

J Med Chem. 2009 Jan 22;52(2):425-32. doi: 10.1021/jm801285t.

PMID:
19113865
14.

Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.

Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC.

Nucl Med Biol. 2009 Aug;36(6):591-603. doi: 10.1016/j.nucmedbio.2009.03.006.

PMID:
19647165
15.

A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging.

Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X.

Amino Acids. 2011 Jul;41(2):439-47. doi: 10.1007/s00726-010-0762-5. Epub 2010 Oct 10.

16.

Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.

Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X.

J Nucl Med. 2009 Jul;50(7):1168-77. doi: 10.2967/jnumed.108.061739. Epub 2009 Jun 12.

17.

Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.

Stott Reynolds TJ, Schehr R, Liu D, Xu J, Miao Y, Hoffman TJ, Rold TL, Lewis MR, Smith CJ.

Nucl Med Biol. 2015 Feb;42(2):99-108. doi: 10.1016/j.nucmedbio.2014.10.002. Epub 2014 Oct 13.

PMID:
25459113
18.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

19.
20.

New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.

Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A.

Nucl Med Biol. 2012 Oct;39(7):962-9. doi: 10.1016/j.nucmedbio.2012.05.007. Epub 2012 Jun 26.

PMID:
22739362
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk